Research Use Only. This page is a category-level identity and evidence comparison for laboratory research. It does not provide advice on human use, treatment, administration, dosing, performance or metabolic outcomes.
This category contains chemically different research materials rather than a single peptide class. NAD+ is a dinucleotide cofactor; MOTS-c and SS-31 are peptides; 5-Amino-1MQ is a small molecule; and L-carnitine is an amino-acid-derived quaternary ammonium compound. Their grouping in one catalogue section should therefore never be treated as evidence of interchangeability.
Comparison matrix
| Comparison field | NAD+ | MOTS-c | SS-31 / elamipretide | 5-Amino-1MQ | L-carnitine |
|---|---|---|---|---|---|
| Commercial owner | NAD+ 1000mg | MOTS-c 40mg | SS-31 10mg | 5-Amino-1MQ 50mg | L-Carnitine 600mg/ml — 10ml |
| Entity class | Dinucleotide/cofactor; not a peptide. | Mitochondrial-derived peptide in the research literature. | Synthetic mitochondria-targeting tetrapeptide; elamipretide is the recognised generic name in medicine literature. | Small-molecule research compound. | Amino-acid-derived quaternary ammonium compound; the exact solution formulation is product-specific. |
| Research-pathway context | Redox cofactor and substrate in NAD+-consuming enzyme systems. | Studies examine mitochondrial-to-nuclear signalling and cellular stress/metabolic pathways. | Studies examine interactions with mitochondrial membranes and cardiolipin-associated contexts. | Literature discusses nicotinamide N-methyltransferase (NNMT) inhibition as an enzyme-target question. | Studies examine carnitine-dependent acyl-group transport and fatty-acid oxidation systems. |
| Identity / mass field | Do not infer beta/free/salt/hydrate form from a generic database record; verify the supplied form. | Sequence, terminal form, counter-ion and molecular mass require the product/batch record. | Do not equate an RUO material automatically with a licensed elamipretide presentation; verify the exact form. | Verify salt state, stereochemical information and molecular mass from product-specific documentation. | Keep the listed solution strength separate from generic L-carnitine substance information unless formulation documentation establishes the form. |
| Analytical question | Chromatographic and MS methods answer different identity and composition questions for a dinucleotide. | Peptide identity and chromatographic composition require method-aware interpretation. | Peptide identity/mass evidence does not establish equivalence to a regulated medicine. | Small-molecule identity and purity require appropriately validated analytical interpretation. | For a solution, documentation must identify the material and formulation; a generic peptide workflow is not a substitute. |
| Evidence layer | Biochemical and cellular metabolism literature. | Biochemical, cellular and preclinical research; translate cautiously across evidence layers. | Mechanistic, preclinical and human/regulatory literature exist; the medicine boundary is separate from the RUO listing. | Enzyme-target and preclinical research context; avoid broad outcome extrapolation. | Biochemical, transport and metabolism literature; generic substance research does not determine the exact supplied solution. |
| Primary limitation | Entity form is central to interpretation. | Evidence depth and exact supplied form are not implied by category placement. | Licensed-medicine information cannot be transferred to the research product. | Do not convert NNMT target literature into a consumer outcome claim. | Do not infer formulation, compatibility or experimental fit from a general compound description. |
Entity-by-entity evidence context
NAD+ is a cofactor involved in redox chemistry and in NAD+-consuming enzyme systems; it is not a mitochondrial peptide.[1] That classification changes the analytical and experimental questions that should be asked of the material.
MOTS-c is described as a mitochondrial-derived peptide in published research. Its literature should be kept distinct from handling questions, which are owned by the dedicated MOTS-c buffer, pH and aggregation guide.[2]
SS-31/elamipretide has a material regulatory distinction that must remain explicit. In September 2025, the FDA granted accelerated approval to Forzinity (elamipretide) for a defined Barth syndrome medicine context.[3] That fact does not establish that the Core Research RUO material is the same pharmaceutical presentation, is licensed, or is suitable for any clinical use.
5-Amino-1MQ is a small-molecule entity rather than a peptide. Its matrix position is therefore defined by target-oriented research questions, including NNMT-related work, not by an assumed metabolic benefit. L-carnitine is also not a peptide; its research context includes carnitine-dependent acyl-group transport systems.[4] The precise form in the Core Research solution should remain document-led.
How to choose the correct research material for an experimental design
Begin by deciding which entity class the assay needs: a redox cofactor, a peptide, a small molecule or a formulated solution. Then document the expected molecular identity, the mechanism or pathway under examination, the analytical evidence required, and whether the exact form is verified in the available product record. This process prevents a broad “metabolism” label from substituting for molecular identity.
For analytical-release interpretation, use the analytical release criteria guide and the Certificate of Analysis portal. The matrix itself is not a batch certificate and does not establish product-form purity, counter-ion or stability.
What this comparison does not establish
This comparison does not rank materials as better, stronger or safer, and does not establish an intervention, preparation method, administration route or human outcome. It does not imply that all category members have comparable research depth, regulated status, physicochemical properties or analytical requirements.
Related research resources
- NAD+ and Metabolism Research Catalogue
- NAD+ 1000mg, MOTS-c 40mg, SS-31 10mg, 5-Amino-1MQ 50mg and L-Carnitine solution
- MOTS-c handling context
- Analytical release criteria
- Batch Certificate of Analysis Verification
References
- Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015. For broad NAD+ cofactor context, see also NAD+ metabolism and cellular processes.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. PMC4350682. Used only for entity and evidence-layer context.
- US Food and Drug Administration. FDA grants accelerated approval to first treatment for Barth syndrome. 19 September 2025. FDA announcement.
- Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 2016. PubMed 26791349.